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Background: Patients with resistant hypertension (RH) represent a high-risk subset of patients with hypertension (HTN). We sought to identify the 
prevalence and impact on long-term adverse outcomes of RH in stable hypertensive outpatients with risk factors for or established atherothombotic 
disease enrolled in the international, prospective REACH registry.
Methods: RH was defined as a BP of ≥ 140/90 mm Hg at baseline visit (≥ 130/80 mm Hg if diabetes or renal insufficiency), with the use of ≥ 3 
antihypertensive medications, including a diuretic. Outcomes up to 4 years were compared between patients with RH and those with non-RH HTN. 
RH patients were also stratified based on number of antihypertensive medications (3, 4, ≥ 5), and outcomes compared. All analyses were conducted 
using multivariate Cox regression models, adjusting for age, gender, smoking, diabetes, body mass index, congestive heart failure, atrial fibrillation, 
timing of prior ischemic event, risk factors only vs. established disease, number of diseased vascular territories, baseline medication use, and 
geographic distribution.
Results: There were 53,530 patients included (mean age: 69.0 ± 9.9 years, established disease: 81%) in the anlaysis. The overall prevalence of 
RH at baseline was 12.7% (6.2% on 3 agents, 4.6% on 4 agents, and 1.9% on ≥ 5 agents). Patients with RH (versus those with non-RH HTN) had a 
higher risk of the primary endpoint of cardiovascular death/myocardial infarction/stroke at 4 years on multivariate analysis (Hazard Ratio [HR] = 
1.13, 95% confidence intervals [CI] 1.05-1.21; p=0.0017). This was mostly driven by increased stroke risk (HR=1.23, 95% CI 1.09-1.39, p=0.0012). 
On subgroup analysis, patients on ≥ 5 agents had the highest risk for occurrence of the primary endpoint as compared with those on 3 agents 
(HR=1.24, 95% CI 1.06-1.45, p=0.0082) (Figure).
Conclusions: RH is prevalent among hypertensive patients with risk factors for or established atherothrombotic disease. It is associated with a 
23% increase in the risk of stroke at 4 years. There is a direct correlation between severity of RH and adverse clinical outcomes. Early consideration 
for other therapeutic interventions in these patients may be necessary.
